Head and Neck Neuroendocrine Carcinoma (HNNE)

Overview

Head and Neck Neuroendocrine Carcinoma encompasses neuroendocrine tumors arising in head and neck sites (excluding sinonasal olfactory neuroblastoma, which is classified as ONBL). It sits under OHNCA (Other Head and Neck Cancer) in OncoTree. These are rare tumors with limited molecular characterization; NGS profiling can identify actionable alterations.

Cohorts in the corpus

• hnc_mskcc_2016 — 3 HNNE cases included in 151 recurrent/metastatic head and neck tumors profiled by MSK-IMPACT 410-gene panel at Memorial Sloan Kettering Cancer Center PMID:27442865.

Recurrent alterations

• Specific alteration frequencies not reported for the 3-patient HNNE subset in the MSK-IMPACT cohort; contribute to the overall finding that 21% of 135 advanced head and neck tumors harbored potentially actionable alterations PMID:27442865.

Subtypes

• Not further subclassified in the corpus.

Therapeutic landscape

• As part of the MSK-IMPACT cohort, HNNE patients with actionable alterations were matched to basket trials PMID:27442865.

Sources

• PMID:27442865 — Morris et al. 2017 (JAMA Oncol). 3 HNNE cases in MSK-IMPACT advanced head and neck cohort; contributes to basket-trial rationale.

This page was processed by crosslinker on 2026-05-14.